CLOBETASOL PROPIONATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and suppression of immune response via modulation of gene expression.
| Metabolism | Primarily hepatic via CYP3A4; systemic absorption minimal with topical use but can be significant with extensive application or occlusion. |
| Excretion | Primarily fecal (biliary) with minimal renal excretion. Less than 5% of a topical dose is recovered in urine as metabolites; the majority is eliminated via feces after hepatic metabolism. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours after topical application. However, due to prolonged cutaneous retention, clinical effects may persist beyond systemic elimination. |
| Protein binding | Approximately 96-99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (transcortin). |
| Volume of Distribution | Not well characterized after topical use due to minimal systemic absorption. After intravenous administration in studies, Vd is approximately 1.0 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical: Minimal systemic absorption, typically <5% through intact skin, but can increase to 20-30% in areas with compromised barrier (e.g., inflamed skin, occlusive dressings). Oral: Not applicable; clobetasol is not administered orally due to extensive first-pass metabolism. |
| Onset of Action | Topical: Visible improvement in 24-48 hours for dermatoses; intralesional: onset within minutes to hours for local anti-inflammatory effect. |
| Duration of Action | Topical: Duration of effect for dermatoses is 12-24 hours after a single application, requiring twice-daily dosing for sustained suppression. Intralesional: effects may last 1-2 weeks. |
| Molecular Weight | 466.97 |
Apply topically as a thin film to affected areas once to twice daily. Maximum 50 g/week. Treatment duration not to exceed 2 consecutive weeks.
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for topical use. Systemic absorption is minimal; however, use with caution in severe renal impairment due to potential for increased systemic exposure. |
| Liver impairment | No specific dose adjustment guidelines for topical use. Caution in severe hepatic impairment (Child-Pugh C) due to potential for decreased metabolism and increased systemic effects. |
| Pediatric use | Not recommended for children under 12 years of age due to increased risk of systemic toxicity. For children 12 and older, apply sparingly to affected area once to twice daily, limit to small areas, and use for shortest duration necessary (typically ≤2 weeks). |
| Geriatric use | Use with caution due to higher risk of skin atrophy and systemic absorption. Apply sparingly to affected areas, limit treatment duration, and avoid occlusive dressings. Consider intermittent dosing schedules. |
| 1st trimester | Insufficient human data; based on animal studies, potential risk cannot be ruled out. Avoid use unless clearly needed. |
| 2nd trimester | Limited human data; topical corticosteroids are generally considered low risk when used in small amounts for short periods. Avoid prolonged use on large areas or under occlusion. |
| 3rd trimester | Avoid prolonged use or large areas due to potential for fetal adrenal suppression. Use only if benefit outweighs risk. |
Clinical note
No significant drug interactions Systemic absorption can cause reversible HPA axis suppression with potential for glucocorticosteroid insufficiency.
| Placental transfer | Minimal placental transfer following topical application; systemic absorption is low. However, large areas or occlusive use may increase transfer. |
| Breastfeeding | Excretion into breast milk is unknown but minimal with topical use. Avoid application to breasts and limit use to small areas, short duration. Caution if applied to large areas or under occlusion. |
■ FDA Black Box Warning
No boxed warning.
| Common Effects | Skin atrophy |
| Serious Effects |
Hypersensitivity to clobetasol or any componentUntreated bacterial, fungal, or viral skin infections
| Precautions | Cushing's syndrome, Hypothalamic-pituitary-adrenal axis suppression with prolonged use, Rebound effect upon discontinuation, Skin atrophy, striae, telangiectasias, Systemic toxicity if used on large surface areas, Not recommended for use on face, groin, or axillae due to increased risk of atrophy, Avoid in patients with known hypersensitivity to corticosteroids |
| Food/Dietary | No known food interactions. However, avoid excessive alcohol consumption as it may exacerbate skin conditions like psoriasis. |
Loading safety data…
| Lactation Rating | L3 - Limited data |
| Teratogenic Risk | Pregnancy category C. In animal studies, corticosteroids have been shown to be teratogenic. Topical application of clobetasol propionate in pregnant animals resulted in fetal abnormalities. In humans, sufficient data are lacking. Risk cannot be ruled out; use only if potential benefit justifies risk. First trimester: avoid due to theoretical risk of cleft palate; second and third trimesters: use with caution, avoid prolonged or extensive use. |
| Fetal Monitoring | Monitor for maternal adrenal suppression, skin atrophy, and infection. In fetus or neonate, monitor for signs of intrauterine growth restriction (IUGR) and adrenal insufficiency if used extensively. Consider growth scans if chronic use in pregnancy. |
| Fertility Effects | No adequate studies on fertility in humans. In animal studies, corticosteroids at high doses may impair fertility. Limited data; no specific recommendations for fertility effects. |
| Clinical Pearls | Clobetasol propionate is a super-high-potency topical corticosteroid. Use for short-term (≤2 weeks) treatment of moderate to severe plaque psoriasis, eczema, and other corticosteroid-responsive dermatoses. Avoid use on face, groin, axillae, or under occlusive dressings due to increased systemic absorption. Do not exceed 50 g/week. Monitor for HPA axis suppression with prolonged use, especially in children and patients with liver failure. Do not use for rosacea, perioral dermatitis, or acne. Taper upon discontinuation to avoid rebound. |
| Patient Advice | Apply a thin layer only to affected skin areas; do not use on broken skin or open wounds. · Do not cover the treated area with bandages or wraps unless directed; avoid use on face, groin, or underarms. · Wash hands after application unless treating hands. · Do not use longer than prescribed (usually 2 weeks); continuous use increases risk of side effects. · Do not use for any condition other than the one prescribed; avoid contact with eyes. |